Differential fates of antibiotics in sulfur-driven autotrophic denitrification: Ciprofloxacin transformation linked to sulfide oxidation
Environmental Research · 2026-09 · 306 · 125348
DOI: 10.1016/j.envres.2026.125348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Environmental Research, 2026-09. Verfasst von Jingsheng Qian und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Environment and Safety Engineering, Fuzhou University, Fuzhou, 350116, China. Hauptthemen laut MEDLINE: Denitrification, Anti-Bacterial Agents, Sulfides, Water Pollutants, Chemical. Die Arbeit nennt 69 Literaturangaben. Gefördert von: Fuzhou University, Fujian Provincial Natural Science Foundation.
Abstract (Originalsprache)
The coexistence of residual antibiotics in wastewater raises concerns about the functional stability of sulfur-driven autotrophic denitrification (SDAD) mediated by sulfur-oxidizing bacteria (SOB) and the fate of antibiotics during treatment. This study investigated the functional tolerance of SOB to three representative antibiotics-ciprofloxacin (CIP), oxytetracycline (OTC), and sulfamonomethoxine (SMM)-under 360-min batch exposure and elucidated their removal behaviors during SOB-mediated sulfide (S2-) oxidation and NO3-/NO2- reduction. Batch experiments revealed distinct fates among the three antibiotics. OTC was removed to a limited extent via adsorption, and SMM remained largely stable. In contrast, CIP exhibited selective transformation closely associated with active S2- oxidation, rather than NO3-/NO2- reduction, with removal efficiency increasing from 11.6 ± 1.7% to 38.1 ± 0.3% as the initial S2- concentration rose from 0 to 12 mg-S/L. Notably, none of the three antibiotics significantly inhibited SOB-mediated S2- oxidation or NO3-/NO2- reduction under 360-min batch exposure, indicating appreciable short-term functional tolerance of the enriched SOB community. Five CIP transformation products were tentatively identified, with predicted lower ecotoxicity than the parent compound. A proof-of-concept sequential-substrate experiment further demonstrated that reintroducing S2- after denitrification substantially enhanced CIP removal, supporting the validity of a phased sulfur-based treatment strategy. To gain mechanistic insight, AlphaFold 3-based molecular docking analyses were performed, which suggested that S2- enhanced the association between CIP and sulfide-quinone oxidoreductase, with calculated binding energy decreasing from -5.2 to -7.0 kcal/mol in the presence of S2-, whereas no such change was observed for OTC or SMM. These findings advance the understanding of antibiotic removal in SDAD systems and provide a basis for mechanism-guided process optimization in the treatment of antibiotic-containing low C/N wastewaters.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Environment and Safety Engineering, Fuzhou University, Fuzhou, 350116, China.
- College of Environment and Safety Engineering, Fuzhou University, Fuzhou, 350116, China. Electronic address: xuem.chen@hotmail.com.
Förderung
- Fuzhou University
- Fujian Provincial Natural Science Foundation
Zitieren
APA
Qian, J., Liao, X., Shi, Y., & Chen, X. (2026). Differential fates of antibiotics in sulfur-driven autotrophic denitrification: Ciprofloxacin transformation linked to sulfide oxidation. Environmental Research, 306, 125348. https://doi.org/10.1016/j.envres.2026.125348
Vancouver
Qian J, Liao X, Shi Y, Chen X. Differential fates of antibiotics in sulfur-driven autotrophic denitrification: Ciprofloxacin transformation linked to sulfide oxidation. Environmental Research. 2026;306:125348. doi:10.1016/j.envres.2026.125348
BibTeX
@article{Qian2026,
author = {Qian, Jingsheng and Liao, Xiaxue and Shi, Yuanji and Chen, Xueming},
title = {Differential fates of antibiotics in sulfur-driven autotrophic denitrification: Ciprofloxacin transformation linked to sulfide oxidation},
journal = {Environmental Research},
year = {2026},
volume = {306},
pages = {125348},
doi = {10.1016/j.envres.2026.125348}
}
EUVIMED